收藏切换
Review of health technology assessment reports in the UK and Canada and its enlightenment to clinical comprehensive evaluation of drugs in China
收藏切换
Yashi LIU1, 2, Mei LU1, 2, Pingping LI1, 2, Yue WANG1, 2, Yan LI1, 2, Bingqi HU1, 2, Siyue WANG1, 2, Xiaoyu YAN1, 2, Wenhao GUO1, 2, Hongchao LI1, 2, *
World Clinical Drug | 2023, 44(5) : 445 - 450
Less
收藏切换
World Clinical Drug | 2023, 44(5): 445-450
• Topic •
Review of health technology assessment reports in the UK and Canada and its enlightenment to clinical comprehensive evaluation of drugs in China
Full
Yashi LIU1, 2, Mei LU1, 2, Pingping LI1, 2, Yue WANG1, 2, Yan LI1, 2, Bingqi HU1, 2, Siyue WANG1, 2, Xiaoyu YAN1, 2, Wenhao GUO1, 2, Hongchao LI1, 2, *
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 200098, Jiangsu Province, China
  • 2.Pharmacoeconomics Evaluation Research Center, China Pharmaceutical University, Nanjing 200098, Jiangsu Province, China
Published: 2023-05-10 doi: 10.13683/j.wph.2023.05.008
Outline
收藏切换

The article drew on the health technology assessment reports of the UK and Canada to provide suggestions for the development of comprehensive clinical evaluation of drugs in China. The completed full health technology assessment reports published by the United Kingdom (UK) and Canada from January 1, 2015 to August 4, 2022 were retrieved from the international HTA database on the official website of International Network of Agencies for Health Technology Assessment (INATA). Microsoft excel was used to extract the dimension information such as safety, effectiveness, cost-effectiveness and other key information in the HTA report, and descriptive statistical analysis was performed. A total of 325 HTA reports were finally included. Effectiveness, cost-effectiveness, and safety accounted for the highest proportions of evaluation dimensions, which were 250 (77%), 233 (72%), and 195 (60%), respectively. In addition, 153 (47%) reports assessed other dimensions. Among the 103 drug-related HTA reports, effectiveness, safety and cost-effectiveness accounted for the highest proportions of evaluation dimensions, which were 89 (86%), 83 (81%) and 73 (71%), respectively. In addition, 30 (29%) drug-related HTA reports assessed other dimensions. In conclusion, the comprehensive clinical evaluation of drugs in China can learn from the following characteristics of HTA reports of the UK and Canada to further improve its working mechanism: clarify the questions that need to be addressed in the comprehensive clinical evaluation of drugs, rationally select the dimensions of comprehensive clinical evaluation of drugs, carrying out comprehensive clinical evaluation of drugs starting from literature review, cost-effectiveness evaluation usually requires the team to carry out the original research to complete, budget impact analysis is only carried out with clear evidence users and necessity, multi-criteria decision analysis may not be an essential part of the HTA report itself, a comprehensive clinical evaluation of a drug can only answer limited questions.

health technology assessment  /  comprehensive clinical evaluation of drugs  /  evaluation dimensions  /  multi-criteria decision analysis
刘雅诗, 卢玫, 李萍萍, 王悦, 李严, 胡冰琪, 王思月, 闫笑雨, 郭文昊, 李洪超. 英国和加拿大卫生技术评估报告对中国药品临床综合评价的启示. 世界临床药物, 2023 , 44 (5) : 445 -450 . DOI: 10.13683/j.wph.2023.05.008
Yashi LIU, Mei LU, Pingping LI, Yue WANG, Yan LI, Bingqi HU, Siyue WANG, Xiaoyu YAN, Wenhao GUO, Hongchao LI. Review of health technology assessment reports in the UK and Canada and its enlightenment to clinical comprehensive evaluation of drugs in China[J]. World Clinical Drug, 2023 , 44 (5) : 445 -450 . DOI: 10.13683/j.wph.2023.05.008
Year 2023 volume 44 Issue 5
9
3
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.05.008
  • Receive Date:2022-11-12
  • Online Date:2026-11-18
  • Published:2023-05-10
Article Data
Affiliations
History
  • Received:2022-11-12
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 200098, Jiangsu Province, China
    2.Pharmacoeconomics Evaluation Research Center, China Pharmaceutical University, Nanjing 200098, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.05.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT